LLY - Sorrento Therapeutics on COVID-19 Therapy Competition: Our Antibody Is Better Than Theirs
In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) discuss the company's therapeutic antibodies to treat COVID-19, the disease caused by the novel coronavirus.
Mark Brunswick, senior vice president of regulatory affairs at Sorrento, claims that the company's antibodies are better than the ones being developed by Eli Lilly (NYSE: LLY) and Regeneron (NASDAQ: REGN) . Henry Ji, chairman, president, and CEO of Sorrento, explains how the company engineered the antibodies to remove the likelihood of antibody-dependent enhancement (ADE), a phenomenon in which the antibody binding to the virus enhances the entry of the virus into the cell.
For further details see:
Sorrento Therapeutics on COVID-19 Therapy Competition: "Our Antibody Is Better Than Theirs"